Core Announcement

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX), valued at $3.63 billion, disclosed Phase 2 data for its oral ACTH‑receptor antagonist atumelnant targeting congenital adrenal hyperplasia (CAH) and ACTH‑dependent Cushing’s syndrome. The announcement coincided with a 4.7% rise in the company’s share price over the preceding week and a strong‑buy consensus among analysts, with price targets reaching $97.

Clinical Trial Results – CAH (Cohort 4)

In Cohort 4 of the Phase 2 CAH trial, presented at the Endocrine Society’s Annual Meeting, eight participants received 80 mg of atumelnant once daily while their glucocorticoid doses were tapered to physiologically normal levels. At week 12, the mean percentage change from baseline in morning serum androstenedione was –67%. Seven of the eight participants who completed the 12‑week course achieved a physiologic daily glucocorticoid dose. Mean reductions from baseline at week 12 were –64% for 11‑OHA4 and –56% for 11‑KT. No treatment‑related severe or serious adverse events were reported across any dose level.

Previously, data from Cohorts 1‑3, in which participants maintained their glucocorticoid doses, showed mean androstenedione reductions of –58% at 40 mg, –70% at 80 mg, and –80% at 120 mg.

Clinical Trial Results – ACTH‑Dependent Cushing’s Syndrome (Phase 1b/2a)

A separate Phase 1b/2a trial in ACTH‑dependent Cushing’s syndrome enrolled six participants who received 40 mg of atumelnant once daily for ten days. Early‑morning serum cortisol decreased in all six participants. Urinary free cortisol remained at or below the upper limit of normal in three of the six participants at the end of the dosing period.

Development Pipeline

The company confirmed that Phase 3 trials in both adult and pediatric populations are currently enrolling.

Financial Performance – Q1 2026

Crinetics reported first‑quarter 2026 revenue of $10.7 million, exceeding the consensus forecast of $8.51 million by 25.73%. Earnings per share were –$1.23, a modest improvement over the anticipated –$1.28.

Patient‑Support Initiative

The firm launched “Everyday Advocacy,” a patient‑education program focused on endocrine diseases. The program provides digital resources, a mobile application for tracking acromegaly symptoms, and workshops, overseen by a steering committee comprising five patient‑advocacy organizations.

Analyst Coverage and Outlook

Citizens reiterated its Market Outperform rating for Crinetics, maintaining a price target of $95 and highlighting the strength of the Palsonify launch. An InvestingPro note indicated that analysts anticipate sales growth in the current year as the Phase 3 trials progress.